RadioMedix
Highly Engaged Employees
Highly Engaged EmployeesManufacturing · Texas, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
9701 Richmond Ave Ste 222, Houston, Texa...Phone Number
(713) 358-6500Website
www.radiomedix.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
2
1
1
1
1
1
About RadioMedix
RadioMedix, Inc. is a clinical stage biotechnology company based in Houston, Texas, specializing in the development and commercialization of targeted alpha and beta therapies, as well as next-generation diagnostic imaging agents. The company utilizes isotopes such as Ac-225, Lu-177, Pb-212, Pb-203, and Ga-68 to address challenging cancers. With a focus on innovation and precision, RadioMedix aims to transform cancer diagnosis and treatment through robust partnerships and a strong pipeline. Their commitment to patient impact drives their mission to disrupt the standard of care in oncology.Explore more
RadioMedix Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is RadioMedix your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Check out if RadioMedix is spiking on competitors!
Product Launch: Get notified when RadioMedix launches new products
Funding: Get notified immidiatlly once RadioMedix has new funding data
Website visits: Recent activity has been detected on your website
Click to see if RadioMedix had a recent Job posting/layoffs
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Earning: See what the market has to say on RadioMedix recently announced quarterly report
RadioMedix, which may be a good buyer, showed buying intent in Masked Content Topic
Congratulate Masked Content for being promoted to Masked Content at RadioMedix
Check if RadioMedix has recently received funding, and reach out quickly before it becomes old news!
Recommended Actions
Reach out to Masked Content who joined RadioMedix as Masked Content
Find more new buyers
Compare Similar Companies to RadioMedix
Compare insights from companies similar to RadioMedix, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
RadioMedix is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
RadioMedix is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about RadioMedix.
RadioMedix financials insights
Gather financial insights about RadioMedix, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2022
Series A
$40M
RadioMedix Tech Stack
A closer look at the technologies used by RadioMedix
Most Recent Scoops
Person-Based
Person-Based
Person-Based
Person-Based
Person-Based
RadioMedix News & Media
RadioMedix to Present at SNMMI 2026 and Mark 20 Years of Radiopharmaceutical Innovation
Company’s SNMMI week activities highlight scientific progress and two decades of advancing precision nuclear medicine for patients with hard-to-treat cancers Company’s SNMMI week activities highlight scientific progress and two decades of advancing precision nuclear medicine for patients with hard-to-treat cancersRadioMedix Expands Thorium-228 Supply Network Through New Agreement With Van Overeem Nuclear B.V.
This agreement expands RadioMedix’s access to essential 228Th resources, strengthening the Company’s 212Pb pipeline and generator platform for its long-term Targeted Alpha Therapy strategyRadioMedix and Thor Medical enter supply agreement for thorium-228
OSLO, Norway and HOUSTON, Dec. 04, 2025 (GLOBE NEWSWIRE) -- Thor Medical ASA, a leading emerging supplier of alpha-emitters for next-generation precision cancer treatment, and RadioMedix, Inc., a U.S. based clinical-stage biotechnology company focused on innovative targeted radiopharmaceuticals for diagnosis, monitoring and cancer therapy, have entered into a five-year frame agreement for the supply of thorium-228 (Th-228). The supply of Th-228 will start in 2026, with volumes scaling with increPress Release: ESMO: AlphaMedixTM phase 2 data support first-in-class potential of new targeted alpha therapy in gastroenteropancreatic neuroendocrine tumors
ESMO: AlphaMedixTM phase 2 data support first-in-class potential of new targeted alpha therapy in gastroenteropancreatic neuroendocrine tumors New...
Read more news
Top Manufacturing Companies
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding RadioMedix
Sign Up For FreeTo access detailed company insights
RadioMedix, Inc. is a clinical stage biotechnology company based in Houston, Texas, specializing in the development and commercialization of targeted alpha and beta therapies, as well as next-generation diagnostic imaging agents. The company utilizes isotopes such as Ac-225, Lu-177, Pb-212, Pb-203, and Ga-68 to address challenging cancers. With a f... Read More
